Clinical significance of hypoxia-inducible factor-1α messenger RNA expression in locally advanced non-small-cell lung cancer after platinum agent and gemcitabine chemotherapy followed by surgery

Clinical Lung Cancer

Volumn 6, Issue 5, 2005, Pages 299-303

  Felip, Enriqueta ^a   Taron, Miquel ^b   Rosell, Rafael ^b   Mendez, Pedro ^b   Queralt, Cristina ^b   Sanchez Ronco, Maria ^c   Sanchez, Jose Javier ^c   Sanchez, Jose Miguel ^b   Maestre, Jose ^a   Majo, Joaquim ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Angiogenesis; Cisplatin; Polymerase chain reaction; Vascular endothelial growth factor

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA;

ADULT; ADVANCED CANCER; AGED; ANGIOGENESIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; SURVIVAL TIME; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

EID: 20744432192     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2005.n.009     Document Type: Article

References (18)

1. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 2004; 22:330-353.
2. Cardenal F, López-Cabrerizo MP, Antón A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 1999; 17:1-7.
3. Crino L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999; 17:3522-3530.
4. Van Zandwijk NV, Smit EF, Kramer GWP, et al. Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). J Clin Oncol 2000; 18:2658-2664.
5. Betticher DC, Schmitz SFH, Tötsch M, et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 2003; 21:1752-1759.
6. Semeza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721-732.
7. Escuin D, Simons JW, Giannakakou P. Exploitation of the HIF axis for cancer therapy. Cancer Biol Ther 2004; 7:e64-e67.
8. Krafft AE, Duncan BW, Bijwaard KE, et al. Optimization of the isolation and amplification of RNA from formalin-fixed, paraffin-embedded tissue: the Armed Forces Institute of Pathology Experience and Literature Review. Mol Diagn 1997; 2:217-230.
9. Cappuzzo F, Selvaggi G, Gregorc V, et al. Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable stage IIIA-bulky N2 and stage IIIB non-small cell lung cancer. Cancer 2003; 98:128-134.
10. Rosell R, Felip E, Taron M, et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin Cancer Res 2004; 10:4215s-4219s.
11. Taron M, Rosell R, Felip E, et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004; 13:2443-2449.
12. Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1 alpha in hypoxia-mediated apoptosis, cell proliferation and tumor angiogenesis. Nature 1998; 394:485-490.
13. Mabjeesh NJ, Escuin D, LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003; 3:1-13.
14. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res 1999; 59:5830-5835.
15. Stoeltzing O, McCarty MF, Wey JS, et al. Role of hypoxia-inducible Factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst 2004; 96:946-956.
16. Sohda M, Ishikawa H, Masuda N, et al. Pretreatment evaluation of combined HIF-1 alpha, p53, and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. Int J Cancer 2004; 110:838-844.
17. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumors and survival. Br J Cancer 2001; 85:881-890.
18. Swinson DE, Jones JL, Cox G, et al. Hypoxia-inducible factor-1 alpha in non-small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int J Cancer 2004; 111:43-50.